JMJoseph J. Mazza

Joseph J. Mazza

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Joseph J. Mazza has a total of 28 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

    • 1 April 2015
      • Vol. 114  (2) , 61-5

    A Review of Clinical Signs Related to Ecchymosis.

    by Narendranath Epperla, Joseph J Mazza, Steven H Yale

    Ecchymosis is a large area of discoloration caused by extravasation of blood into the subcutaneous tissue. It is an objective physical finding that may provide valuable clues as to its possible etiology. Ecchymosis is associated with eponyms based on the physician who first described the physical findings, which can be divided into 4 anatomical categories: base of the skull, abdominal wall and retroperitoneum, groin and scrotum, and lower extremity. Classic external signs and eponyms associated with ecchymosis are reviewed. Knowledge of these signs on physical examination may prove to be a useful clue directing the examiner to consider potentially serious causes of disease.


    • 1 February 2015
      • Vol. 114  (1) , 16-20

    Factors that affect rate of INR decline after warfarin discontinuation.

    by James K Burmester, Richard L Berg, John R Schmelzer, Joseph J Mazza, Steven H Yale

    Despite vast literature on warfarin, optimal strategies for temporarily discontinuing and restarting warfarin have not been established. To improve warfarin discontinuation processes, we investigated known medical and genetic factors that influence stable warfarin dose to determine how well they predict the time until patients become subtherapeutic after discontinuing warfarin. This was a retrospective cohort study of patients who temporarily discontinued warfarin before an elective procedure andhad at least 2 international normalized ratio (INR) values available during the discontinuation period. Data abstracted included date of discontinuation, warfarin dose, INR values, body surface area, gender, age, indication for warfarin, current medications, eGFR, and presence of bridging therapy with heparin. DNA variants were tested in CYP2C9, VKORC1, and CYP4F2 genes. Subjects were excluded if they received vitamin K, fresh frozen plasma, or prothrombin complexes to reverse anticoagulation. Asymptotic regression models were used to approximate decline in INR during warfarin clearance. Spearman correlations and Kruskal-Wallis tests were used to characterize associations of model estimates with quantitative variables and for group comparisons, respectively. Other than the expected association with baseline INR, correlations of model parameter estimates with clinical variables were generally weak and not statistically significant. The strongest associations with slope were with serum creatinine and eGFR. There were no significant associations with CYP2C9, VKORC1, or CYP4F2 DNA variants, but there were few subjects combined in the nonwild groups for CYP2C9. Estimated slope showed moderate correlation with observed dose. Known clinical and genetic predictors of therapeutic dose were not found to be strongly associated with the slope of INR decline after warfarin discontinuation.


    • 1 December 2014
      • Vol. 113  (6) , 242-5

    Mirtazapine and mefloquine therapy for non-AIDS-related progressive multifocal leukoencephalopathy.

    by Narendranath Epperla, Rafael Medina-Flores, Joseph J Mazza, Steven H Yale

    Progressive multifocal leukoencephalopathy (PML) is an opportunistic infection of the human nervous system caused by the JC virus. We report what is, to the best of our knowledge, the second reported case using a combination of mefloquine and mirtazapine in a patient with non-AIDS-related PML with a good clinical outcome. Conversely, the recent trial of mefloquine in 21 patients with AIDS and 3 without AIDS failed to show a reduction of JC viral DNA levels in the cerebral spinal fluid. However, the positive clinical response seen in our patient after the initiation of this combination therapy suggests that further studies in the form of randomized controlled trials for the treatment of non-AIDS-related PML are warranted.


  • Open Access

    Anti-Phospholipid Antibodies in Patients Undergoing Total Joint Replacement Surgery

    by Melissa Simpson, Michael J. Sanfelippo, Adedayo A. Onitilo, James K. Burmester, William Hocking, Steven H. Yale, Joseph J. Mazza

    Background. Patients undergoing joint replacement remain at increased risk for venous thromboembolism (VTE) compared to other types of surgery, regardless of thromboprophylactic regimen. The pathophysiologic processes rendering this group of patients at risk for VTE are multifactorial. Procedure-specific and patient-specific exposures play a role in the postoperative development of VTE, including the development of anti-phospholipid antibodies (aPL). Methods. We measured three aPL (anti-cardiolipin, anti-β2 glycoprotein, and lupus anticoagulant) in 123 subjects undergoing total knee or hip arthroplasty to describe the presence of these antibodies preoperatively and to describe the rate of postoperative seroconversion among those people who were negative preoperatively. Postoperative antibodies were measured at day 7, 14, and 21. Results. The prevalence of aPL antibodies in the preoperative period was 44%, positive subjects were more likely to be smokers (P=0.05) and were less likely to have undergone a previous arthroplasty procedure (P=0.002). Subjects seroconverted in a 21 day postoperative period at a rate of 79%. Conclusions. These pilot data suggest that the prevalence of aPL in this population both preoperatively and postoperatively is higher than previously expected. Further studies are needed to describe aPL in a larger population and to establish their clinical significance in populations undergoing joint replacement surgeries.


  • Multilocular thymic cyst with epithelioid granulomata of unknown etiology: a radiologic and histopathologic correlation

    by Yusuf Kasirye, Stephen Talsness, Matthew P. Walters, John W.E. Douglas-Jones, Jeffrey M. Resnick, Joseph J. Mazza, Steven H. Yale


    • 1 June 2011
      • Vol. 110  (3) , 127-31

    The Emeritus Clinical-Researcher Program.

    by Steven Yale, Michael Jones, Stephen D Wesbrook, Stephen Talsness, Joseph J Mazza

    For some physicians, retirement means leaving their practice and severing ties with their institution, while others may wish to maintain a more active role within their institution. Many institutions have designed programs that enable these individuals to maintain an academic relationship and provide services to their institution. This manuscript provides a brief experience of the Marshfield Clinic (MC) and Marshfield Clinic Research Foundation (MCRF) recent development of an emeritus program for research and education. The program is designed to provide opportunities for physicians, clinical PhDs, dentists, and other clinicians with terminal degrees and the necessary qualifications as researchers, to continue to contribute to the MC/MCRF research mission after retirement from clinical practice. Assignment to various aspects of the program is determined by the individual's expertise, experience and institutional needs. Expectations and performance of each individual is evaluated. The infrastructure of the program was assembled by reviewing institutes that have had an emeritus program in operation and integrating the unique aspect of MC/MCRF resources. Alignment of the unique skills, expertise, knowledge, and wealth of experience of emeritus faculty along institutional needs has provided added value to the institution without major financial investment.

    • 1 April 2011
      • Vol. 110  (2) , 82-4

    Rhabdomyolysis-induced acute kidney injury secondary to Anaplasma phagocytophilum and concomitant statin use.

    by Stephen R Talsness, Sanjay K Shukla, Joseph J Mazza, Steven H Yale

    We report the case of a patient with rhabdomyolysis-induced acute renal failure occurring in the setting of Anoplasma phagocytophilum infection based on the presence of morulae in neutrophils and concomitant statin use. Although the pathogenesis is unknown, we believe the combination of concurrent statin use in the setting of the infection promoted this complication. We describe proposed mechanisms including cytokine activation, alteration of the muscle membrane components, and ionic balance as contributing factors.


    • 1 February 2011
      • Vol. 110  (1) , 14-20

    The impact of serum glucose on clinical outcomes in patients hospitalized with community-acquired pneumonia.

    by Desiree A Godar, David R Kumar, Kate M Schmelzer, Stephen R Talsness, Hong Liang, John R Schmelzer, Joseph J Mazza, Steven H Yale

    Community-acquired pneumonia (CAP) is a common medical condition resulting in excess morbidity, mortality, and high rates of hospitalization. Despite high hospitalization rates for CAP, the relationship between abnormal glucose levels (hyperglycemia and hypoglycemia) and the seriousness of the illness as measured by length of stay (LOS) is not well established. We examined relationships of CAP to multiple factors that impact predictability and severity of the disease process. They include glycemic control; hospital utilization, including LOS; 30-day hospital readmission; intensive care unit (ICU) admissions, adjusting for comorbidities; illness severity; and timing of antibiotic treatment. We conducted a retrospective observational cohort study of adult patients hospitalized for CAP between January 1, 1992 and June 23, 2007. Case screening was conducted electronically using International Classification of Diseases, 9th Revision (ICD-9) codes 480.0-487.9. Subsequent medical record abstraction yielded 969 qualifying cases with comprehensive data on past and current medical problems. Serum glucose levels at admission were independently associated with LOS for CAP patients. Patients with levels between 90 mg/dL and 140 mg/dL on admission had shorter LOS compared to those with levels of < 90 mg/dL and > 140 mg/dL (median 3.9 vs 4.2 days, P = .04). Multivariate analyses confirmed the univariate results. Serum glucose levels at initial hospitalization were not associated with 30-day hospital readmission (P =.34) or ICU admission (P = .48). Abnormal glucose levels are an independent predictor of increased LOS for CAP. Control of blood glucose may lead to improved outcomes, including shortened LOS, and should be a priority in CAP management.


    • 1 February 2009
      • Vol. 108  (1) , 35-9

    New oral anticoagulants: a brief review.

    by Joseph J Mazza, Steven H Yale

    This manuscript represents a brief review of the current oral anticoagulants that have come on the scene over the past decade and that are now in various stages of development through the process of phase II and III clinical trials. A brief review of the oral thrombin and direct factor Xa inhibitors is presented to apprise the practicing clinician of the status of these new agents. Efficacy and safety issues are mentioned as they relate to each agent and the need for alternative agents to replace the vitamin K antagonists for long-term anticoagulation therapy. Although none of the agents discussed in the review have been approved for clinical use, data accumulated thus far from the clinical studies have provided some degree of encouragement and optimism for their future approval.